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ABSTRACT
Background
The complexity and heterogeneity of the human plasma proteome have presented
significant challenges in the identification of protein changes associated with tumor
development. Refined genetically engineered mouse (GEM) models of human cancer have
been shown to faithfully recapitulate the molecular, biological, and clinical features of human
disease. Here, we sought to exploit the merits of a well-characterized GEM model of pancreatic
cancer to determine whether proteomics technologies allow identification of protein changes
associated with tumor development and whether such changes are relevant to human
pancreatic cancer.
Methods and Findings
Plasma was sampled from mice at early and advanced stages of tumor development and
from matched controls. Using a proteomic approach based on extensive protein fractionation,
we confidently identified 1,442 proteins that were distributed across seven orders of
magnitude of abundance in plasma. Analysis of proteins chosen on the basis of increased
levels in plasma from tumor-bearing mice and corroborating protein or RNA expression in
tissue documented concordance in the blood from 30 newly diagnosed patients with
pancreatic cancer relative to 30 control specimens. A panel of five proteins selected on the
basis of their increased level at an early stage of tumor development in the mouse was tested
in a blinded study in 26 humans from the CARET (Carotene and Retinol Efficacy Trial) cohort.
The panel discriminated pancreatic cancer cases from matched controls in blood specimens
obtained between 7 and 13 mo prior to the development of symptoms and clinical diagnosis of
pancreatic cancer.
Conclusions
Our findings indicate that GEM models of cancer, in combination with in-depth proteomic
analysis, provide a useful strategy to identify candidate markers applicable to human cancer
with potential utility for early detection.
The Editors’ Summary of this article follows the references.
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A major goal of the cancer biomarker ﬁeld is the develop-
ment of noninvasive tests that allow early cancer detection.
Blood constituents, notably plasma proteins, reﬂect diverse
physiologic or pathologic states. The ease with which this
compartment can be sampled makes it a logical choice for
screening applications to detect cancer at an early stage.
However, the vast dynamic range of protein abundance in
plasma and the likely occurrence of tumor-derived proteins
in the lower range of protein abundance represent major
challenges in the application of proteomic-based strategies
for cancer biomarker identiﬁcation [1,2]. Recent experience
in comprehensive proﬁling of plasma proteins indicates that
low-abundance proteins may be identiﬁed with high con-
ﬁdence following extensive plasma fractionation and with the
use of high-resolution mass spectrometry [3,4].
Genomic analyses of human and mouse cancers have
revealed signiﬁcant concordance in chromosomal aberra-
tions and expression proﬁles, establishing cross-species
analyses as a highly effective ﬁlter in the identiﬁcation of
genes and loci embedded within complex cancer genomes [5–
8]. Genetically engineered mouse (GEM) models afford
deﬁned stages of tumor development, homogenized breeding
and environmental conditions, and standardized blood
sampling thereby reducing biological and nonbiological
heterogeneity. The concept that plasma from GEM models
of cancer contains tumor-derived proteins that may be
relevant as candidate markers for human cancer is attractive
as suggested by SELDI (surface enhanced laser desorption/
ionization) scanning technology, but it remains untested as
no markers demonstrated to be applicable to human cancer
have been identiﬁed using such models and methods [9].
In this study, we focused our efforts on pancreatic ductal
adenocarcinoma (PDAC)—a highly lethal cancer character-
ized by activating mutations of the Kras oncogene and
inactivation of the Ink4a and Arf-p53 tumor suppressor
pathways in the great majority of cases [10]. Kras activation
is thought to initiate focal lesions in the pancreatic ducts,
known as pancreatic intraepithelial neoplasias (PanINs),
which undergo graded histological progression to PDAC in
association with subsequent Ink4a and Arf-p53 inactivation
[11,12]. The recent generation of mice harboring these
signature genetic mutations has yielded models that closely
recapitulate the histopathogenesis of the human disease with
Kras
G12D initiating focal PanINs that rapidly undergo multi-
stage progression in conjunction with Ink4a/Arf or p53
mutations, resulting in invasive PDAC. Importantly, these
models show broadly conserved tumor biology and molecular
circuitry similar to human PDAC. The tumors exhibit a
proliferative stroma (desmoplasia) and frequent metastases,
express pancreatic ductal markers (CK-19) and apical mucins
(e.g., Muc1, Muc5AC), show activation of developmental
signaling pathways (Hedgehog, Notch, EGFR), and harbor
syntenic genomic alterations to human PDAC [9,13–15].
We have applied here an intensive quantitative proteomic
analysis strategy to plasmas that were sampled from this
pancreatic cancer mouse model at early stage, representing
PanIN, and at advanced stage of tumor development,
representing PDAC, and from corresponding matched con-
trols. With this approach, we sought to explore the merits of
this well-characterized GEM model of pancreatic cancer to
determine whether our proteomics technology allows iden-
tiﬁcation of protein changes associated with tumor develop-
ment and whether such changes are relevant to human
pancreatic cancer.
Materials and Methods
Mice and Plasma Pooling
The mice for proteomics analysis were obtained by breeding
Pdx1-Cre Ink4a/Arf
lox/lox and Kras
G12D Ink4a/Arf
lox/lox mice [13].
All mice were bred ﬁve generations onto an FVN/n genetic
background. Experimental Pdx1-Cre Kras
G12D Ink4a/Arf
lox/lox
mice and control Kras
G12D Ink4a/Arf
lox/lox and Pdx1-Cre Ink4a/
Arf
lox/lox mice were euthanized at age 5.5 or 7 wk (Figure 1).
Lethal comas were induced by injecting mice IP with a 0.6–0.8
ml 5% Avertin (2,2,2-Tribromoethanol, Sigma-Aldrich, part
number T4,840–2). Blood was obtained by cardiac puncture
using a 1-ml syringe with 22-gauge needle. Blood was placed
in K3EDTA coated tubes (Fisher) and centrifuged at 4 8C for 5
min at 3,000 rpm. The supernatant (plasma) was removed and
frozen in 100 ll aliquots on dry ice and stored at 80 8C. In all
cases, the mice were subjected to autopsy, and the pancreas
was ﬁxed for histological analysis. Mice were excluded from
the study if they exhibited extra-pancreatic pathology as is
observed in a subset of Pdx1-Cre Kras
G12D mice [9]. Pooling of
samples was based on age as well as the extent of the disease
based on histological examination. For early stage PanIN pool
(PanIN-1 to PanIN-3 lesions) plasma analysis, median age of
the mice was 5.5 wk, while for PDAC plasma analysis median
age was 7 wk. Approximately one-third of the Kras Ink4a/Arf
mice present with the most common pathology observed in
human cases—glandular. Thus, in our selection of mice with
PDAC, we only used the corresponding plasma if the tumor
areas were almost exclusively glandular (i.e., less than ;5%
nonglandular pathologies). Age matched controls were used
for both PanIN and PDAC. All mice were male.
Sample Preparation
PDAC, PanIN, and respective control plasma pools
obtained from seven to eight individual mice (1 ml of each
pool) were individually immunodepleted of the top three
most abundant proteins (albumin, IgG, and transferrin) using
a Ms-3 column (4.63250 mm; Agilent). Brieﬂy, columns were
equilibrated with buffer A at 0.5 ml/min for 13 min, and
aliquots of 75 ll of the pooled sera were injected after
ﬁltration through a 0.22-lm syringe ﬁlter. The ﬂow-through
fractions were collected for 10 min at a ﬂow rate of buffer A
of 0.5 ml/min, combined and stored at  80 8C until use. The
column bound material was recovered by elution for 8 min
with buffer B at 1 ml/min. Subsequently, immunodepleted
samples were concentrated using Centricon YM-3 devices
(Millipore) and rediluted in 8 M urea, 30 mM Tris (pH 8.5),
0.5% OG (octyl-beta-d-glucopyranoside, Roche). Samples
were reduced with DTT in 50 lL of 2 M Tris-HCl (pH 8.5)
(0.66 mg DTT/mg protein), and isotopic labeling of intact
proteins in cysteine residues were performed with acryla-
mide. Normal control samples received the light acrylamide
isotope (D0 acrylamide) (.99.5% purity, Fluka), and PDAC
and PanIN cancer samples received the heavy 2,3,39-D3-
acrylamide isotope (D3 acrylamide) (.98% purity, Cam-
bridge Isotope Laboratories). Alkylation with acrylamide was
performed for 1 h at room temperature by adding to the
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acrylamide per milligram protein, diluted in a small volume
of 2 M Tris-HCl (pH 8.5) [16].
Protein Fractionation
The two sets of samples (PDAC 3 control and PanIN 3
control) were processed in the same identical way. The 2-D
protein fractionation has been performed on the basis of the
Intact-Protein Analysis System (IPAS) approach [3,17,18],
with some modiﬁcations. The workﬂow is summarized in
Figure 2. Brieﬂy, after isotopic labeling, the cancer plasma
pool and normal pool were mixed, diluted to 10 ml with 20
mM Tris in 6% isopropanol, 4 M urea (pH 8.5), and
immediately injected in a Mono-Q 10/100 column (Amersham
Biosciences) for the anion-exchange chromatography, the
ﬁrst dimension of the protein fractionation. The buffer
system consisted of solvent A (20 mM Tris in 6% isopropanol,
4 M urea [pH 8.5]) and solvent B (20 mM Tris in 6%
isopropanol, 4 M urea, 1 M NaCl [pH 8.5]). The separation was
performed at 4.0 ml/min in a gradient of 0% to 35% solvent B
in 44 min; 35% to 50% solvent B in 3 min; 50% to 100%
solvent B in 5 min; and 100% solvent B for an additional 5
min. A total of 12 pools were collected and run individually in
reversed-phase chromatography, the second dimension of the
process. The reversed-phase fractionation was carried out in
a Poros R2 column (4.6 3 50 mm, Applied Biosystems) using
TFA/Acetonitrile as buffer system (solvent A: 95% H2O, 5%
Acetonitrile, 0.1% TFA and solvent B: 90% Acetonitrile, 10%
H2O, 0.1% TFA) at 2.7 ml/min. The gradient used was 5%
solvent A until absorbance reached base line (desalting step)
and then 5%–50% solvent B in 18 min; 50%–80% solvent B
in 7 min; and 80%–95% solvent B in 2 min. Sixty fractions of
900 ll were collected during the run, corresponding to a total
of 720 fractions. Aliquots of 200 ll of each fraction,
correspondent approximately of 20 lg of protein, were
separated for mass-spectrometry shotgun analysis.
Mass Spectrometry Analysis
For protein identiﬁcation we performed in-solution
trypsin digestion with the lyophilized aliquots of the 720
individual fractions. Individual digested fractions 4 to 60
from each reversed-phase run were pooled in 13 pools,
corresponding to a total of 156 fractions for analysis from
each PDAC and PanIN experiments. Digests were analyzed in
a LTQ-FT mass spectrometer (Thermo-Finnigan) coupled to
a nano-Aquity nanoﬂow chromatography system (Waters).
The liquid chromatography separation was performed in a
25-cm column (Picofrit 75 lm ID, New Objectives, in-house-
packed with MagicC18 resin) using a 90-min linear gradient
from 5% to 40% of acetonitrile in 0.1% formic acid at 250 nl/
min. The spectra were acquired in a data-dependent mode in
m/z range of 400 to 1,800, with selection of the ﬁve most
abundant þ2o rþ3 ions of each MS spectrum for MS/MS
analysis. Mass spectrometer parameters were: capillary
voltage of 2.1 KV, capillary temperature of 200 8C, resolution
of 100,000, and FT target value of 2,000,000.
Protein Identification
The acquired data were automatically processed by the
Computational Proteomics Analysis System (CPAS) [19].
Searches were performed considering cysteine alkylation
with the light form of acrylamide as a ﬁxed modiﬁcation and
heavy form of acrylamide (þ3.01884) as a variable modiﬁca-
tion. For the identiﬁcation of proteins with false discovery
rate (FDR) , 1%, LC/MS/MS spectra of PDAC and PanIN
samples were subjected to tryptic and semi-tryptic searches
Figure 1. PanIN and PDAC Mice for Plasma Proteomic Analyses
(A) Pdx1-Cre Ink4a/Arf
lox/lox and Kras
G12D Ink4a/Arf
lox/lox mice at average of 5.5 and 7 wk of age representing PanIN and PDAC lesions, respectively, were
selected on the basis of histological analysis of tumor for this study.
(B and C) show representative histology for PanIN and PDAC stages. Plasma was pooled from each disease group and each corresponding age and sex-
matched controls to yield 1 ml per phenotype for proteomic analysis.
doi:10.1371/journal.pmed.0050123.g001
PLoS Medicine | www.plosmedicine.org June 2008 | Volume 5 | Issue 6 | e123 0955
Plasma Proteome of PDAC and PanIN Modelsagainst a database consisting of forward and reversed mouse
IPI databases released in 01/2006 (v.3.12) using X!Tandem
[20]. The database search results were then analyzed by
PeptideProphet [21] and ProteinProphet [22] programs. Our
high conﬁdence list of identiﬁcations retained proteins with
ProteinProphet scores   0.95 and two or more peptides per
protein. For PDAC, 18,409 unique peptides corresponding to
1,040 proteins were identiﬁed in forward sequence, whereas
only eight peptides corresponding to four proteins were
identiﬁed in reversed sequence, resulting in a false positive
identiﬁcation rate for peptides of 8/18,409 or 0.04%, and
proteins of 4/1,040 or 0.4%. For PanIN, 16,319 unique
peptides, corresponding to 559 proteins were identiﬁed in
forward sequence, whereas only ﬁve peptides, corresponding
to two proteins were identiﬁed in reversed sequence, and this
resulted in a false positive identiﬁcation rate for peptides of
5/16,319 or 0.03%, and proteins of 2/559 or 0.4%. A secondary
list of protein identiﬁcations with less than 5% FDR consisted
of tryptic searches using the same algorithm and databank,
but only proteins with ProteinProphet score . 0.7 and
PeptideProphet score . 0.2 were retained. The result with
,1% FDR searches were later appended with data from the
5% FDR searches on the basis of external cross-correlated
biological information from different sources, such as tissue
speciﬁcity or mRNA expression in pancreatic cancer. The
number of MS events (spectral counts) was obtained for all
the proteins with less than 5% FDR (including less than 1%
FDR) from tryptic searches only.
Quantitative Analysis of Acrylamide Isotopes
The quantitative approach consisted of differential labeling
of peptides containing cysteine with acrylamide isotopes
(heavy or light) [16]. Quantitative information was extracted
using a script designated ‘‘Q3’’ that was developed in-house to
obtain the relative quantiﬁcation for each pair of peptides
identiﬁed by MS/MS that contains cysteine residues [16]. Only
peptides with a minimum of 0.75 PeptideProphet score and
mass deviation inferior to 20 ppm were considered. Peptide
isotopic ratios were plotted in logarithmic scale in a histo-
gram and the median of the distribution was centered at zero.
This normalization approach was chosen since the great
majority of proteins were not expected to be dysregulated in
cases compared to controls (Figure S1). All normalized
peptide ratios for a speciﬁc protein were averaged to compute
an overall protein ratio. Proteins with quantitative informa-
tion presented as ‘‘cancer only,’’ only had detected peptides
labeled with the heavy form of acrylamide. All peptide and
protein ratios were calculated in logarithmic scale, but
reported in linear scale. Statistical signiﬁcance of the protein
quantitative information was obtained via two procedures: (i)
for those proteins with multiple peptides quantiﬁed, a p-value
for the mean log-ratio, which has mean zero under the null
hypothesis, was calculated using one-sample t-test; (ii) for
proteins with a single paired MS event, the probability for the
ratio was extrapolated from the distribution of ratios in a
control-control experiment whereby the same sample was
labeled with heavy and light acrylamide (Figure S1).
mRNA Analysis of Pancreatic Tissue
Total pancreas RNA was isolated from wild-type FVB/n
mice using the Trizol reagent protocol (Invitrogen) with the
slight modiﬁcations; in brief, freshly harvested pancreas was
homogenized in 15 ml Trizol, centrifuged, and the aqueous
layer was extracted with chloroform, and ﬁnally isopropanol
precipitation was performed by adding 0.5 volumes high salt
buffer (0.8 M NaCitrate/1.2 M NaCl) and 0.5 volume
Figure 2. Schematic of Mouse Plasma Proteomic Analysis
Pools of plasma from PanIN and PDAC mice along with corresponding controls were similarly processed and combined after differential isotopic
labeling. Subsequent protein fractionation involved anion-exchange and reversed-phase chromatography. Individual fractions were analyzed by LC–
MS/MS after in-solution digestion. Data were processed using Computational Proteomics Analysis System (CPAS).
doi:10.1371/journal.pmed.0050123.g002
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using the RNAeasy kit (Qiagen). Total RNA from PDAC
arising in Pdx1-Cre LSL-KrasG12D Ink4a/Arﬂox/lox mice was
extracted using the Trizol Reagent and then by RNAeasy
using the standard protocols. Expression proﬁling of normal
pancreas (n¼2 specimens) and PDAC RNA (n¼4 specimens)
was performed on Affymetrix 430 A2.0 microarrays.
Histology and Immunohistochemistry
Tissue sections were ﬁxed in 10% formalin. Parafﬁn-
embedded 6–8-lm sections of the pancreas were used for
histological and immunohistochemical (IHC) studies. The
following primary antibodies were used: tumor necrosis
factor receptor superfamily member 1a precursor
(TNFRSF1A) (Abcam); anti-human TNF RI/TNFRSF1A anti-
body (R&D Systems); TIMP-1 Ab-2 mouse mAb (Lab Vision
Corporation); monoclonal anti-human TIMP-1 antibody
(R&D Systems); protein tyrosine phosphatase receptor type
gamma (PTPRG) polyclonal antibody (Orbigen); Human/
Mouse/Rat Tenascin C Mab (R&D Systems); Mouse ALCAM
Biotinylated Afﬁnity Puriﬁed Pab (R&D Systems); and CD166
(ALCAM) mouse monoclonal antibody (Novocastra). Sections
for immunohistochemistry were deparafﬁnized with xylol
and rehydrated. After the washing steps with PBS, antigen
retrieval was performed by microwave heating the slides for
10 min in Antigen Unmasking Solution (Vector). The slides
were then washed in PBS and incubated for 10 min in 1%
H2O2, rinsed with PBS, and incubated 1 h in blocking solution
(5% normal serum þ 0.3% Triton X-100). Hybridization with
the primary antibody was carried out overnight at 4 8C. After
PBS rinse, secondary antibody (Jackson Immunoresearch) was
incubated for 1 h. The manufacturer’s protocols were used
for ABC and DAB substrates (Vector); slides were counter-
stained with hematoxylin (Vector) and dehydrated in 40%,
70%, 90%, and 100% ethanol.
ELISA
Mouse ALCAM, tissue inhibitor of metalloproteinase 1
(TIMP1), and intercellular adhesion molecule 1 (ICAM1)
(R&D Systems) measurements were performed according to
manufacturer’s protocol in aliquots of the same mice used for
the plasma proteomic analysis. For ALCAM, mouse plasma
dilution was 1:8. Human ALCAM, insulin-like growth factor
binding protein 4 (IGFBP4), sTNFRSF1, TIMP1 (R&D
Systems), ICAM1 (Biosource), neutrophil gelatinase-associ-
ated lipocalin (LCN2) (Antibody Shop), lithostathine 1
(REG1A) (Biovendor), and regenerating islet-derived protein
3 (REG3) (Pancrepap) measurements were performed on sera
from PDAC, matched controls, and pancreatitis using
commercially available ELISAs according to the manufac-
turer’s protocol. HE4 measurements were performed accord-
ing to Scholler et al. [23]. Additionally, PDAC and matched
controls sera were also assayed for carbohydrate antigen 19.9
(CA 19–9) (Alpha Diagnostic International). All sera samples
and standards were run in duplicate with absorbance
measured on the SpectraMax Plus 384 and results calculated
with SoftMax Pro v4.7.1 (Molecular Devices).
Statistical Analysis of ELISA Data
Prior to statistical analysis, all candidate markers had their
protein concentration standardized on the basis of the
control group concentration mean. In that way all candidate
marker concentrations have mean 0 and variance 1 in the
control group. In short, if mu0 and sd0 are the mean and
standard deviation of a candidate marker, their standardized
concentration (Y9) will be Y9 ¼ (y   mu0)/sd0. This method
facilitates cross-candidate marker comparison and places all
markers on the same scale [24,25]. p-Values for individual
markers were computed using the nonparametric Wilcoxon
rank-sum test. To avoid over-ﬁtting issues, composite markers
summarizing a panel were generated using a predeﬁned
combination rule that considers the panel positive if any
individual marker is positive (e.g., exceeds a threshold on the
standardized scale). p-Values that measure whether the AUC
of the composite markers are statistically different from
CA19.9 were computed using a method described by DeLong
et al. [26].
Human Samples
Newly diagnosed serum samples from patients were
obtained at the time of diagnosis following informed consent
using IRB-approved guidelines from the University of
Michigan. A total of 30 serum samples were obtained from
patients with a conﬁrmed diagnosis of pancreatic adenocar-
cinoma who were seen in the Multidisciplinary Pancreatic
Tumor Clinic at the University of Michigan Comprehensive
Cancer Center. Anonymous serum samples from the pancre-
atic cancer patients were randomly selected from a clinic
population that consists of 15% of individuals presenting
with early stage (i.e., stage 1/2) disease and 85% presenting
with advanced stage (i.e., stage 3/4). The information on
individual characteristics is presented in Table S1. Inclusion
criteria for the study consisted of conﬁrmed diagnosis of
pancreatic cancer, the ability to provide written informed
consent, and the ability to provide 40 ml of blood. Exclusion
criteria included chemotherapy or radiation therapy prior to
blood draw and a diagnosis of other malignancies within 5 y
from the time of blood draw. Sera were also obtained from 15
patients with chronic pancreatitis who were seen in the
Gastroenterology Clinic at University of Michigan Medical
Center and from 20 control healthy individuals collected at
the University of Michigan under the auspices of the Early
Detection Research Network (EDRN). The mean age of the
tumor group was 65 y and of the chronic pancreatitis group
was 54 y. Individuals from whom control sera were obtained
were age and sex matched to the tumor group. All of chronic
pancreatitis sera were collected in an elective setting in the
clinic in the absence of an acute ﬂare. All blood and sera were
collected and processed using the same standardized proto-
col. Blood samples were maintained at room temperature for
30–60 min to allow the clot to form and then centrifuged at
1,300 3 ga t48C for 20 min. The serum was removed,
transferred to a polypropylene capped tube in 1 ml aliquots,
and frozen. The frozen samples were stored at  70 8C until
assayed. All serum samples were labeled with a unique
identiﬁer. None of the samples were thawed more than twice
before analysis.
To address the relevance of proteins observed up-regulated
in the PanIN stage mouse model plasma, we submitted a
proposal to the Carotene and Retinol Efﬁcacy Trial (CARET),
a cohort study that involved 18,314 individuals with increased
cancer risk, to do a blinded validation study of our relevant
proteins. CARET identiﬁed all individuals (13) in this cohort
from whom blood was collected approximately a year prior to
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time when they were completely asymptomatic, as well as
matched controls that were not diagnosed with cancer over a
4-y follow-up period, irrespective of their state of general
health otherwise. The information on individual character-
istics is presented in Table S2.
Results
Proteomic Analysis of Mouse Plasma
Plasma obtained from PDAC-prone mice engineered with
activated Kras and Ink4a/Arf deﬁciency [13] was subjected to
proteomic analysis. The study was designed to test directly
whether current proteomics technologies allow for quantita-
tive analysis and identiﬁcation of protein changes associated
with tumor development in the mouse and whether such
changes have relevance to human tumors.
Mice harboring Pdx1-Cre Kras
G12D Ink4a/Arf
lox/lox mutations
exhibit stereotypical neoplastic progression from pancreatic
cancer precursor lesions (PanINs) present at ;2 wk of age to
advanced PDAC by 6 to 10 wk of age [13]. A plasma pooling
strategy was applied for in-depth proteomic analysis. Blood
was obtained from mice at the PanIN stage and at the PDAC
stage (at 5.5 and 7 wk, respectively) and from age and sex
matched controls, thus constituting four pools of plasma
(Figure 1). To guarantee a good homogeneity among pooled
plasma samples, the tumor stage was conﬁrmed for individual
mice by histopathology prior to pooling. For quantitative
proteome analysis, we applied differential isotopic labeling to
each tumor pool and its matched control [16], followed by
extensive fractionation of intact proteins [3]. The exper-
imental workﬂow is presented in Figure 2.
Each experiment generated 156 plasma fractions on the
basis of anion-exchange and reversed-phase chromatography,
which were analyzed separately by liquid chromatography–
tandem mass spectrometry (LC–MS/MS) following tryptic
digestion. Some 2,800,000 mass spectra were produced and
analyzed in this study. Collectively, the PanIN and PDAC
experiments resulted in a primary list of 1,095 unique high
conﬁdence proteins with ,1% FDR on the basis of reverse-
database searches (Table S3 presents the full list of protein
identiﬁcations). To this primary list, we appended 347
additional proteins with ,5% FDR (Table S4). The latter
proteins had corresponding mRNA expression in pancreas
tissue .2-fold compared to the mean of 61 mouse tissue
expression surveys from published data [27] and/or mRNA
expression in pancreatic cancer .2-fold compared to normal
tissue, in mouse (this study) or human (prior study [28]).
On the basis of UniProt keywords, 25% of identiﬁed
proteins in the list of 1,442 proteins contained a signal
peptide for secretion, and 20% were annotated as glycopro-
teins. Of note, the list contained a relatively large percentage
(9%) of membrane proteins on the basis of Gene Ontology
cellular component annotation. Peptides for several mem-
brane proteins identiﬁed were derived exclusively from the
extracellular domain. Epidermal growth factor receptor, for
example, was detected in several fractions with peptides
spanning amino acids 25 to 647 representing the extracellular
N-terminal domain. These results are consistent with shed-
ding of extracellular domains into the circulation [29].
To estimate the concentration range of mouse plasma
proteins identiﬁed, we correlated spectral counting data
(number of MS2 events/protein) [30] to known concentrations
of proteins in plasma (http://www.rulesbasedmedicine.com/).
We observed a signiﬁcant correlation between spectral counts
for a given protein and its plasma protein concentration (R
2
¼ 0.84) (Figure 3A). From this analysis, we estimated that our
proteomic approach allowed for identiﬁcation of plasma
proteins across seven orders of magnitude and detection of
some proteins in mouse plasma at concentrations as low as 1
ng/ml. In addition, the number of proteins identiﬁed was
greater at lower predicted plasma concentrations on the basis
of spectral counts (Figure 3B), indicating substantial depth of
analysis achieved with extensive protein fractionation.
The majority of medium to high abundance proteins were
detected in both PanIN and PDAC experiments, while most
differences in protein identiﬁcations between the two experi-
ments represented lower abundance proteins (Figure S2A).
Likewise, in duplicate LC–MS/MS analysis of the same
fractions, most differences in protein identiﬁcations ob-
served represented lower abundance proteins (Figure S2B).
Similar experiments in which independent replicates of
samples were analyzed resulted in 60% of protein sampling/
identiﬁcation in both experiments [3]. These differences in
protein identiﬁcations between the two experiments are
largely attributed to mass spectrometry limitations in
dynamic range and speed, speciﬁcally when analyzing com-
plex samples such as plasma. In addition to mass spectrom-
etry limitations, some of the differences observed between
the two experiments may result from occurrence of some
proteins at a higher level of abundance at the PDAC stage
compared to PanIN. Importantly, since in each experiment
(PDAC and PanIN) cancer and respective control samples
were analyzed together after isotopic labeling followed by
mixing, methodological variations related to fractionation
and sample processing were minimized.
Tumor Related Changes in Mouse Plasma
We used acrylamide isotopic labeling of cysteine residues
to obtain relative quantitative information between disease
and control samples. This labeling approach is chemically
very efﬁcient as evidenced by lack of unlabeled cysteines in
searching mass spectra [16]. Additionally, this labeling
chemistry is fully compatible with the intact protein
approach, without signiﬁcantly affecting protein physical-
chemical characteristics. In duplicate experiments performed
with independent replicates of samples, there were no
proteins that showed quantitative inconsistencies (up-regu-
lated in one experiment and down-regulated in the other)
(unpublished data). Among the 621 quantiﬁed proteins, 165
were found to be up-regulated ( 1.5, p , 0.05) in cancer
samples (PDAC or PanIN or both) compared to controls
(Table S5).
A signiﬁcant proportion of plasma proteins is synthesized
in the liver and may be affected as part of the host response.
To distinguish between such classical plasma proteins from
proteins that may be derived from the pancreas in our
dataset, we cross-referenced the 1,442 proteins identiﬁed in
our analyses with published proteome proﬁles of mouse liver
tissue [31,32]. Approximately 38% of the 1,442 proteins were
identiﬁed in mouse liver tissue, consisting mostly of relatively
abundant plasma proteins. Sixty-seven of these proteins
showed increased levels with tumor development in the
mouse (Table S5). In contrast, proteins estimated to be of low
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tation of pancreatic proteins relative to liver proteins on the
basis of tissue protein and/or mRNA data (Figure S3).
The following criteria were applied to select a subset of
proteins potentially relevant to pancreatic cancer: (i) mean
protein ratio in neoplasm/normal plasma   1.5 (p , 0.05) in
PDAC and PanIN on the basis of isotopic labeling ratios, and/
or occurrence of isotope-labeled peptides in cancer samples
but not in controls; (ii) not known to represent acute-phase
reactants, complement or coagulation proteins according to
Ingenuity Pathway Analysis annotation (Ingenuity Systems)
(Table S5); and (iii) mouse protein has a corresponding
ortholog gene in human. Also included in this list were
proteins that were similarly elevated in either PDAC or
PanIN and that had evidence of increased expression of
corresponding genes in pancreatic cancer for mouse (data
obtained in this study) and for human [28]. These criteria
resulted in subset of 45 proteins of potential interest from the
set of 165 up-regulated proteins (Table 1).
To further support our ﬁndings we measured protein levels
in mouse pancreatic tissue and in mouse plasma for a subset
of up-regulated proteins. These proteins were selected on the
basis of their potential relationship with pancreatic cancer
and the availability of antibodies and ELISA kits with the
requisite speciﬁcity. IHC analysis was done for CD166 antigen
precursor (ALCAM), receptor-type tyrosine-protein PTPRG,
TIMP1, and tenascin C (TNC). All tested proteins demon-
strated strong IHC staining in mouse PanIN and pancreatic
cancer tissue sections (Figure 4). Circulating protein levels of
ALCAM, ICAM1, and TIMP1 in the same mouse plasma used
in the proteomic approach were measured by ELISA (Figure
5). ALCAM, ICAM1, and TIMP1 had signiﬁcantly higher levels
in PDAC mice plasmas. TIMP1 was signiﬁcantly elevated in
PanIN plasma samples as well.
Relevance of Mouse Findings to Human Pancreatic Cancer
The relevance to human pancreatic cancer of proteins up-
regulated in mouse plasma with tumor development was
investigated using human tissue and/or blood samples.
Immunohistochemistry was performed for PTPRG,
TNFRSF1A, and TNC, all of which showed positive IHC
staining in human pancreatic cancer (Figure 3). Data for
ALCAM, ICAM1, LCN2, TNFRSF1A, TIMP1, REG1A, REG3,
WFDC2 (whey-acidic protein [WAP] four-disulﬁde core
Figure 3. Identification of Low Abundance Proteins in Mouse Plasma
(A) Spectral counts (number of MS2-events acquired per protein) in the experiment performed for early stage pancreatic cancer mouse plasma protein
(PanIN) were correlated with protein plasma concentration reported by Rules-Based Medicine (http://www.rulesbasedmedicine.com/case3/Table3.htm).
The 21 proteins used for this estimation were: Serpina1b, Adipoq, A2m, Apoa1, Apoc3, Apoh, B2m, C3, Ceacam1, Crp, Fabp1, F7, Ftl1, Fgb, Hp, Icam1,
Igf1, Mb, Serbp1, Timp1, Vcam1. As an approximation, we estimated the protein concentration with the correlation (log spectral counts¼[0.6233log
protein concentration] þ 0.0625).
(B) Taking into consideration the correlation of spectral counts and protein concentration, we observed an inverse relationship between the total
number of proteins identified and their abundance (number of MS2/proteins).
doi:10.1371/journal.pmed.0050123.g003
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proteins that were up-regulated in plasma from tumor-
bearing mice were assayed in human sera from 30 patients
with PDAC to assess their signiﬁcance individually and as a
panel, together with CA19–9, a marker that is currently in
clinical use as a pancreatic cancer marker (Table 2) [33]. As a
control group, we analyzed sera from 20 matched healthy
individuals and ten to 15 individuals with chronic pancrea-
titis, obtained using the same protocol and storage con-
ditions. Information regarding patient characteristics and
Table 1. Proteins Potentially Relevant to Pancreatic Cancer Revealed by the Proteomic Analysis of Mouse Model Plasma
Criteria for
Candidate
Selection
Name Protein Quantification
* mRNA Expression Previously Analyzed
PDAC
Cancer/
Normal
PanIN
Cancer/
Normal
Human Mouse
Cancer/
Normal
Tissue Plasma Proteomics
b
Cancer/
Normal
Pancreatitis/
Normal
Tissue Pancreatic
Juice
Plasma
Increased levels in
PDAC and PanIN
CD5L 2.7 2.1 0.6 0.7 0.3
CTRB1 6.1 9.1 0.3 0.3 0.3 # [52] " [53], & [54,55]
IL1RAP Cancer only Cancer only 6.4 4.9 0.4
LCN2
a 6.9 Cancer only 13.4 3.8 39.8 IHC [46] & [54]
LRG1 2.9 2.0 — — 1.3 & [54] " [56]
PRG4 10.0 2.5 1.5 1.6 0.7
REG1A
a 2.3 3.9 0.3 0.3 0.4 ELISA [57,58] # [52], "[59] " [53], & [55]]
REG3
a 5.9 2.8 — — 0.7 ELISA [58]
SLPI 1.9 2.3 3.9 1.5 1.9 # [60]
SYCN 4.2 5.0 — — 0.1 # [61]
TIMP1
a Cancer only (1.7)
c 4.1 3.4 22.0 IHC [62] ELISA [51]
Increased levels in
PDAC and increased
expression of
corresponding genes
ALCAM
a 2.8 (0.9)
c 1.1 1.1 2.8 " [52]
COL18A1 Cancer only — 1.2 1.1 13.7
COL15A1 1.8 — 1.2 1.4 5.1
CTGF 2.0 0.8 1.2 3.9 89.6 # [60]
CTSS 2.4 — 3.4 2.8 16.8
CXCL16 2.8 — — — 3.2
FBLN2 2.6 — 4.1 8.2 5.7
FSTL1 6.5 1.1 2.3 3.4 12.7
HTRA1 Cancer only — — — 2.9
ICAM1
a 1.6 0.9 (1.0)
c 2.2 1.5 3.9 IHC [63] ELISA [40]
LIMS1 2.2 — 0.9 0.8 16.3
LTBP4 Cancer only — 1.7 1.9 2.2
LTF 2.3 — 5.7 0.9 17.0 IHC [64] # [60] & [54]
LYZ 3.2 1.1 3.6 2.6 33.3 IHC [65] # [60] & [54]
MSH6 2.3 — 1.0 0.9 3.2
PTPRG
a Cancer only — 2.8 2.4 3.8
SOD3 2.9 0.3 0.5 0.6 4.7 " [59]
SPARCL1 1.6 0.8 1.0 1.9 5.7
TNC
a Cancer only — 6.6 6.9 180.0 IHC [39] ELISA [39]
TNFRSF1A
a 2.5 — 2.4 2.6 1.5 ELISA [41]
VASP 2.3 — 3.8 2.0 4.2
WFDC2
a 2.6 — 2.1 0.9 25.0 IHC [48]
ZDHHC20 Cancer only — — — 3.4
Increased levels in
PanIN and increased
expression of
corresponding genes
CD248 1.3 1.8 — — 6.4
CD97 1.2 2.6 4.0 3.7 9.9 IHC [66] ELISA [66]
CDH1 — 2.0 1.9 0.8 2.6
EFEMP2 1.2 3.1 2.1 3.4 30.0 " [52]
EFNA1 1.0 Cancer only 2.3 1.9 2.6
GKN1 1.6 Cancer only — — 12.9
IGFBP4
a 1.3 1.5 2.7 5.2 37.5
TFF2 — 3.3 4.0 4.6 0.1 IHC [67]
TGFBI — 2.4 3.2 4.7 15.9 # [60], "[52]
THBS1 1.2 3.1 2.5 5.9 2.6 IHC [68] # [60], "[52]
aProteins further validated by immunoassays.
b", up-regulated; #, down-regulated; &, detected.
cMeasurements of protein ratio performed by ELISA for the same mouse plasma samples used in the proteomic analysis.
*p-Value for all ratios ,0.05.
doi:10.1371/journal.pmed.0050123.t001
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performed for individual proteins and for the entire panel as
a group. All but one of the proteins were signiﬁcantly
elevated in cancer compared to one or both control groups (p
, 0.03). Seven proteins were compared between cancer and
both control groups, and ﬁve of seven were signiﬁcant in both
comparisons (p , 0.03) (Figure S4 for box plots, Table 2).
Only one protein (LCN2) did not achieve statistical signiﬁ-
cance. For proteins that yielded statistically signiﬁcant
differences between cancer and healthy individuals, the areas
under the curve (AUCs) ranged between 0.75 and 0.89 (Figure
S5), and between cancer and pancreatitis the AUCs ranged
between 0.74 and 0.92. Of note, a panel of all the proteins
tested, inclusive of those that did not achieve statistical
signiﬁcance individually so as to avoid any overﬁtting, yielded
an AUC of 0.96 in contrast to CA 19–9, which yielded an AUC
of 0.79 (Figure 6A and 6B).
Plasma analysis of mice at the PanIN stage allows us to test
whether protein changes in plasma observed at an early
tumor stage in the mouse may be up-regulated in individuals
with pancreatic cancer before actual clinical diagnosis. To
that effect, a blinded analysis was conducted using sera
collected as part of CARET, which included 18,314 partic-
ipants [34]. The CARET study was intended to test the effect
of daily beta-carotene and retinyl palmitate on cancer
incidence and death in individuals with a history of smoking
or asbestos exposure. All participants (13) in the cohort
diagnosed with pancreatic cancer between 7–13 mo following
a blood draw (mean ¼ 10 mo) and an equal number of
controls that were matched for age, sex, year of CARET
Figure 4. IHC Analysis of Candidate PDAC Biomarkers in Mouse and Human Tissue
Mouse, left photomicrographs: PTPRG expression (A–C). Note islet staining in normal pancreas (A); membranous staining is seen in PanIN and PDAC
epithelium (B and C). TNC expression (D–F). Note lack of staining in normal pancreatic tissue (D); strong expression is present in stroma of PanIN (E) and
PDAC (F). ALCAM expression (G–I). Note membranous staining of the normal pancreatic acinar and ductal cells (G); increased staining is present in the
PanIN epithelium (H) and PDAC cells (I). TIMP1 expression (J–L). Note lack of staining in normal pancreatic tissue (J); staining is observed in association
with acinar-ductal metaplasia (K) and both PDAC stromal and tumor cells (L). (A–C, J–L, magnification 2003; D–I, magnification 4003).
Human, right photomicrographs: PTPRG expression (A, B). Note membranous staining in PDAC epithelium and absence of staining in normal pancreas.
TNC expression (C, D). Note expression in PDAC stroma. TNFRSF1 expression (E, F). Note membranous staining in PDAC epithelium; normal pancreatic
tissue is negative. Dashed red lines subdivide different histology of the tissue analysed, and blue boxes indicate the adjacent magnified region. Six
independent tumor specimens were stained per antibody for mouse IHC and three for human. PTTGF, TNFRSF1, and ALCAM each showed positive
staining in at least 15% of tumor cells. TNC and TIMP1 showed positive staining in at least 50% of stromal cells. A, C, and E, magnification 1003;B ,
magnification 2003; D and F, magnification 4003.
doi:10.1371/journal.pmed.0050123.g004
PLoS Medicine | www.plosmedicine.org June 2008 | Volume 5 | Issue 6 | e123 0961
Plasma Proteome of PDAC and PanIN Modelsenrollment, and time of blood draw in relation to enrollment
and who were not diagnosed with pancreatic cancer on the
basis of information in the CARET database, were identiﬁed
by CARET for the blinded pancreatic cancer validation study.
The pancreatic cancer and control groups were also matched
for CARET intervention. Information regarding CARET
patient characteristics and tumor stage is provided in Table
S2. We tested ﬁve proteins that were up-regulated in mouse
plasma at the PanIN stage (LCN2, REG1A, REG3, TIMP1, and
IGFBP4) together with CA19.9, without knowledge of which
individuals developed pancreatic cancer subsequent to the
blood draw and which individuals were matched controls
(Table 2). When tested individually, two of the ﬁve proteins
(IGFBP4 and TIMP1) showed signiﬁcance at 0.05 and 0.04,
respectively. CA19.9 was signiﬁcant at 0.04. As a panel, the
ﬁve proteins achieved an AUC of 0.817 (p ¼ 0.005), inclusive
of the three proteins that did not achieve statistical
signiﬁcance individually to avoid any overﬁtting. When the
panel of ﬁve proteins was combined with CA19.9, an AUC of
0.911 was achieved (Figure 6C).
Discussion
Our ﬁndings here indicate that plasma proteomic analysis
of GEM models of cancer provide a useful strategy to identify
candidate markers applicable to human cancer with potential
utility for early detection. This is very relevant, since there is
a compelling need to develop blood-based markers that allow
early cancer detection, classify tumors to direct therapy, and
monitor disease progression, regression, or recurrence. Early
detection is particularly relevant to pancreatic adenocarci-
noma, which is the fourth leading cause of cancer death in the
United States and with a 5-y survival rate of only 3%. Because
Figure 5. Validation Study of ALCAM, ICAM1, and TIMP1 in Mouse Plasma by ELISA
(A) Plasma from the same individual mice used for proteomics discovery were utilized for validation by means of ELISA. ALCAM, TIMP1, and ICAM1 were
all elevated in plasma of the PDAC mice.
(B) TIMP1 was also elevated in plasma of PanIN mice. ALCAM overall (cancer plus controls) concentration in mouse plasma was 19 ng/ml; ICAM1 was
163 ng/ml; and TIMP1was 6.2 ng/ml. The low ng/ml concentrations of these proteins support the substantial depth of analysis achieved with our
discovery platform. Normalization of concentration was performed as described in the Materials and Methods.
doi:10.1371/journal.pmed.0050123.g005
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symptoms at an early stage, the disease is often diagnosed at
late stages. In contrast, early stage disease is associated with
prolonged survival following surgical resection of the tumor
[35]. Therefore, improvement in means to detect pancreatic
cancer early would be expected to impact outcome.
While published studies have pointed to the merits of
proteomics for cancer marker identiﬁcation, the challenge of
discovering markers applicable to early detection has been
substantial. Mass spectrometry has evolved from a tool to
identify and characterize isolated proteins or for mass peak
proﬁling to a platform for interrogating complex proteomes.
However, even with recent improvements in sensitivity and
mass accuracy, the complexity of the plasma proteome far
exceeds the current capabilities of mass spectrometry to fully
resolve their individual protein and peptide constituents in a
single analysis. Current strategies to achieve in-depth cover-
age require sample fractionation followed by separate
analyses of individual fractions or capture of protein or
peptide subsets [2]. The depth of proteomic analysis achieved
in this study through extensive fractionation of intact
proteins and reliance on high-resolution mass spectrometry
has allowed identiﬁcation of low abundance proteins [3]. In
addition, reliance on acrylamide isotope labeling of cysteines
has allowed quantitative measures to be derived from mass
spectrometric analysis of the plasma proteome. More
importantly, the identiﬁcation of proteins is not restricted
to peptides containing cysteine residues, since in our work-
ﬂow there is no capture step of isotopically labeled peptides
as in the isotope-coded afﬁnity (ICAT) method tags [36], thus
providing a comprehensive list of peptides in the digests and
consequently better protein coverage and conﬁdence in
protein identiﬁcation. Such depth of analysis is necessary to
identify potential tumor speciﬁc biomarkers and to extend
discovery beyond abundant protein changes resulting from
inﬂammation or acute-phase reaction. As a result, changes in
plasma proteins relevant to pancreatic cancer could be
identiﬁed across a wide dynamic range of protein abundance.
Some of the proteins identiﬁed in this study as potentially
relevant to pancreatic cancer have already been associated
with cancer, as evidenced from Ingenuity Pathway Analysis. In
total, 13 proteins were previously investigated in pancreatic
cancer tissue or for a smaller number in human blood by
immunoassay (Table 1) and found to be elevated. Among
those, MMP2 and its inhibitor TIMP1 are known to be
involved in tumor progression and extracellular matrix
degradation [37]. REG1A and REG3 are proteins highly
secreted by pancreatic islet cells and have also been described
as potential markers for pancreatic diseases [38]. ICAM1 and
TNC are involved, respectively, in cellular attachment and
inhibition of adhesion of cells to the extracellular matrix
[39,40]. TNFRSF1A, has been associated with the acute-phase
process [41].
Elevated levels of ALCAM, IGFBP4, LCN2, and WFDC2 in
circulation in pancreatic cancer are novel ﬁndings. ALCAM is
a cell adhesion molecule critical to tumor development and
progression [42]. The form of ALCAM detected in circulation,
corresponds to the shed extracellular domain of this integral
membrane protein. The process of shedding is promoted by
metalloproteases [43]. Overexpression of IGFBP4, the small-
est protein from the IGF binding protein family, has been
related to tumor growth [44]. LCN2 has been shown to play a
role in regulating cellular growth and metastasis in colon
cancer [45] and to be overexpressed in pancreatic cancer at
the mRNA levels [46], concordant with gene expression
analysis of tumors from our mouse model (Table 1).
Interestingly, WFDC2 (or HE4), a promising biomarker for
ovarian cancer [47], was found in our study to be up-
regulated in mouse PDAC plasma, with concordant mRNA
expression. Additionally, WFDC2 was listed as up-regulated at
Table 2. ELISA Analysis of Up-Regulated Proteins in Pancreatic Cancer Sera and Prediagnostic Sera
Status of
Diagnosis
Protein
a Cancer Controls Pancreatitis AUC Wilcoxon Rank-Sum
Test (p-Value)
Mean Standard
Deviation
Mean Standard
Deviation
Mean Standard
Deviation
Cancer Versus
Controls
Cancer Versus
Pancreatitis
Cancer Versus
Controls
Cancer Versus
Pancreatitis
Confirmed
Diagnosis
b
CA 19–9
(U/ml)
147.7 75.6 14.7 17.0 65.0 82.0 0.98 0.79 ,0.001 0.007
ALCAM 139.9 65.9 84.2 26.0 96.4 30.6 0.85 0.74 ,0.001 0.008
TIMP1 322.7 196.0 182.3 33.7 178.3 39.3 0.89 0.88 ,0.001 ,0.001
ICAM1 457.4 384.8 270.7 67.8 121.4 64.9 0.75 0.92 0.029 ,0.001
LCN2 162.6 83.8 138.6 49.2 120.3 26.8 0.65 0.61 0.452 0.318
REG1A 1,108.4 624.9 691.3 342.2 1,277.6 1,219.5 0.79 0.57 0.002 0.528
REG3 22.6 15.1 8.6 5.1 11.0 5.9 0.88 0.77 ,0.001 0.011
IGFBP4 153.5 125.6 116.1 74.5 89.6 29.6 0.69 0.74 0.106 0.022
TNFRSF1A 2.8 1.5 1.8 0.9 — — 0.82 — 0.008 —
WFDC2 (HE4) 10.9 18.4 2.5 8.2 — — 0.89 — 0.001 —
Prediagnosis CA19–9 (U/ml) 56.1 74.2 10.6 6.7 — — 0.74 — 0.040 —
TIMP1 212.7 62.4 162.1 36 — — 0.74 — 0.040 —
IGFBP4 61 33.1 45.6 50.5 — — 0.72 — 0.050 —
LCN2 123.5 42.6 104.4 66.1 — — 0.68 — 0.110 —
REG3 25.2 21.7 17.2 14.3 — — 0.65 — 0.220 —
REG1A 2,111.4 1,151.9 2,059.1 1325.1 — — 0.52 — 0.980 —
aAll protein concentrations in human serum, except CA 19–9, are reported in ng/ml.
bThirty human PDAC sera (20 sera for TNFRSF1A and HE4), 20 matched controls, and ten chronic pancreatitis (15 sera for TIMP1 and ALCAM) were assayed for the listed biomarker candidates.
doi:10.1371/journal.pmed.0050123.t002
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study [48], suggesting that this protein may also have
relevance to pancreatic cancer. The whey-acidic protein
(WAP) family has been described to be involved in tumor
progression through the regulation of the NFkB signaling
pathway [49], and a second member of this family, secretory
leucocyte proteinase inhibitor (SLPI), is among our list of
candidates up-regulated in both PDAC and PanIN mouse
samples. PTPRG, a tyrosine phosphatase receptor that was
validated in this study in both mouse and human by
immunohistochemistry, has been recently described in gastric
cancer as a potential tumor suppressor gene that is
methylated in metastatic cells [50].
All together, the prior association of proteins identiﬁed in
this study with cancer and for some with demonstrated
function in pancreatic cancer is indicative of the utility of
mouse models for deciphering protein changes relevant to
pancreatic and other cancers in humans. Also, it should be
emphasized that previously, these proteins were studied
independently of each other and not identiﬁed through a
systematic proﬁling study as presented here.
Because mice can be sampled at deﬁned stages of tumor
development and under controlled breeding conditions,
greater standardization is possible using mouse models
compared to human studies. Mouse models also allowed in
this study investigations at an early stage of tumor develop-
ment (PanIN), allowing identiﬁcation of proteins associated
with early events in tumorigenesis. The strong concordance
between mouse and human pancreatic cancer in both tissue
and circulating markers is striking. From the list of nine
candidate markers found elevated by proteomics and
validated in human samples, only LCN2 was not signiﬁcantly
elevated.
Our analysis of candidate protein markers in newly
diagnosed patient samples conﬁrmed that CA19–9 discrim-
inates pancreatic cancer at the time of diagnosis well from
healthy controls (see Table S1). CA19–9 levels were elevated
in more than 80% of patients compared with healthy
controls. However the sensitivity and speciﬁcity of CA19–9
in other settings relevant to pancreatic cancer, namely in
discriminating between pancreatitis and pancreatic cancer
and for detecting cancer at an early stage, are much reduced
compared with its power to discriminate newly diagnosed
pancreatic cancer and healthy individuals [51], hence the
need for additional markers to constitute a panel with
improved sensitivity and speciﬁcity for discriminating pan-
creatic cancer from pancreatitis and for detecting the disease
at an early stage prior to onset of symptoms. In this respect,
TIMP1 and ICAM1 had superior performance when cancer
samples were compared to samples from pancreatitis
patients. The panel of candidate markers that we tested,
together with CA19–9, signiﬁcantly improved sensitivity and
speciﬁcity in preclinical samples.
The next steps in building on our ﬁndings include
developing high throughput assays for additional candidate
markers identiﬁed, for which such assays are not currently
available, and to expand validation studies to address speciﬁc
applications, notably for implementing a panel-based test to
distinguish between pancreatitis and pancreatic cancer and
to further assess the utility of a panel approach for detecting
pancreatic cancer early among individuals at increased risk of
developing the disease.
Supporting Information
Figure S1. Distribution of Quantitative Events
(A) Equal amounts of total immunodepleted nonfractionated human
plasma were labeled with heavy and light acrylamide and analyzed
Figure 6. ROC in Assays of Human Samples for Two Panels of Proteins Identified in Proteomic Analysis of Plasmas from Tumor-Bearing Mice
ROC curves based on ELISA measurements of ALCAM, ICAM1, LCN2, TIMP1, REG1A, REG3, and IGFBP4 as a panel with or without CA19–9 comparing
pancreatic cancer versus healthy controls (A) and pancreatic cancer versus pancreatitis (B). This panel of candidates was chosen on the basis of up-
regulation in tumor-bearing mice. As expected, CA19–9 performed well in comparisons with healthy individuals as controls; however, the chosen panel
was significantly better than CA19–9 alone when pancreatitis patients were used as controls.
(C) The panel tested with prediagnostic sera (LCN2, TIMP1, REG1A, REG3, and IGFBP4) was chosen on the basis of up-regulation at the PanIN stage. This
panel performed slightly better in comparison to CA19–9 but a combination of CA19–9 with the panel of candidates significantly improved
discrimination between early stage (prediagnostic) sera and matched controls. Standardization procedures and composite marker ROCs were generated
without fitting, by inclusion of all tested candidate markers. Specimens from controls and pancreatitis patients were obtained from the same institution
and with the same protocol for blood collection. For details see Materials and Methods and Tables S1 and S2.
doi:10.1371/journal.pmed.0050123.g006
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Plasma Proteome of PDAC and PanIN Modelswith LC–MS/MS. The histogram represents the distribution of 4,371
quantitative events. From this control-control events distribution, the
number of events that exceeds a given ratio was determined. For
instance, there were 125 up-regulated events (ratio   2.0), which
corresponds to 2.8% (p ¼ 0.028).
(B) Distribution of quantitative events for PDAC experiment. Total, n
¼ 65,640; up-regulated, n ¼ 14,420 (22%).
(C) Distribution of quantitative events for PanIN experiment. Total, n
¼ 58,063; up-regulated, n ¼ 9,396 (16%).
Found at doi:10.1371/journal.pmed.0050123.sg001 (675 KB TIF).
Figure S2. Concordance in Protein Identiﬁcation between PanIN and
PDAC Experiments
(A) High abundant proteins were detected consistently in both PanIN
and PDAC experiments, while low abundant proteins were more
susceptible to sampling limitations in data acquisition for LC–MS/MS.
(B) Protein identiﬁcation concordance between duplicate runs of
fractions. Reversed-phase fractions from anion exchange fraction 6
of both PanIN and PDAC were run in duplicate, and the same
behavior was observed. Protein concentration was estimated on the
basis of spectral counts (Figure 3). The majority of medium to high
abundance proteins (.1 lg/ml or .100 ms events) were detected in
both PanIN and PDAC experiments, while most differences in
protein identiﬁcations between the two experiments represented
lower abundance proteins.
Found at doi:10.1371/journal.pmed.0050123.sg002 (608 KB TIF).
Figure S3. Protein Tissue Distribution Versus Relative Protein
Abundance
The 1,442 proteins identiﬁed were correlated to tissue speciﬁcity
using published datasets from mouse liver proteomic proﬁling studies
[31,32] and one human tissue mRNA expression study [27]. Proteins
estimated to be of low abundance (,100 ng/ml) had a much greater
representation of pancreatic proteins relative to liver proteins based
on tissue protein and/or mRNA. Protein concentration was estimated
on the basis of MS2 events (Figure 2).
Found at doi:10.1371/journal.pmed.0050123.sg003 (270 KB TIF).
Figure S4. Box Plot for ELISA Measurements of Proteins Relevant to
Pancreatic Cancer
A total of 30 human PDAC sera (20 sera for TNFRSF1A and WFDC2),
20 healthy, and ten chronic pancreatitis (15 sera for TIMP1 and
ALCAM) were assayed for the plotted proteins. More statistical detail
about this data is presented in Table 2. The horizontal axis legend
represents: 1, cancer; 2, normal; 3, pancreatitis.
Found at doi:10.1371/journal.pmed.0050123.sg004 (1.4 MB TIF).
Figure S5. Receiver Operating Characteristic Curves for ELISA
Measurements of Proteins Relevant to Pancreatic Cancer
All data points for each individual protein were used in the Receiver
Operating Characteristic (ROC) plots, without applying any cut-off
value. The total number of samples used in this analysis was: 30
human PDAC sera (20 sera for TNFRSF1A and WFDC2), 20 healthy,
and ten chronic pancreatitis (15 sera for TIMP1 and ALCAM).
Detailed statistical information for these proteins is presented in
Table 2.
Found at doi:10.1371/journal.pmed.0050123.sg005 (1.5 MB TIF).
Table S1. Clinical Characteristics and Protein Assay Values for Newly
Diagnosed Pancreatic Cancer Patients
Found at doi:10.1371/journal.pmed.0050123.st001 (25 KB XLS).
Table S2. Clinical Characteristics and Protein Assay Values for
Pancreatic Cancer Patients from the CARET Cohort Study
Found at doi:10.1371/journal.pmed.0050123.st002 (21 KB XLS).
Table S3. Proteins Identiﬁed with ,1% FDR
Found at doi:10.1371/journal.pmed.0050123.st003 (1.2 MB XLS).
Table S4. Proteins Identiﬁed with ,5% FDR and Relevant to
Pancreatic Cancer
Found at doi:10.1371/journal.pmed.0050123.st004 (149 KB XLS).
Table S5. Proteins Up-Regulated in PDAC and/or PanIN Mouse
Plasma
Found at doi:10.1371/journal.pmed.0050123.st005 (79 KB XLS).
Accession Numbers
All the proteomic data generated in this study for the PDAC mouse
model are available in the Mouse Plasma Peptide Atlas Project (http://
www.peptideatlas.org/repository/).
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Background. Cancers are life-threatening, disorganized masses of cells
that can occur anywhere in the human body. They develop when cells
acquire genetic changes that allow them to grow uncontrollably and to
spread around the body (metastasize). If a cancer is detected when it is
still small and has not metastasized, surgery can often provide a cure.
Unfortunately, many cancers are detected only when they are large
enough to press against surrounding tissues and cause pain or other
symptoms. By this time, surgical removal of the original (primary) tumor
may be impossible and there may be secondary cancers scattered
around the body. In such cases, radiotherapy and chemotherapy can
sometimes help, but the outlook for patients whose cancers are detected
late is often poor. One cancer type for which late detection is a particular
problem is pancreatic adenocarcinoma. This cancer rarely causes any
symptoms in its early stages. Furthermore, the symptoms it eventually
causes—jaundice, abdominal and back pain, and weight loss—are seen
in many other illnesses. Consequently, pancreatic cancer has usually
spread before it is diagnosed, and most patients die within a year of their
diagnosis.
Why Was This Study Done? If a test could be developed to detect
pancreatic cancer in its early stages, the lives of many patients might be
extended. Tumors often release specific proteins—‘‘cancer bio-
markers’’—into the blood, a bodily fluid that can be easily sampled. If
a protein released into the blood by pancreatic cancer cells could be
identified, it might be possible to develop a noninvasive screening test
for this deadly cancer. In this study, the researchers use a ‘‘proteomic’’
approach to identify potential biomarkers for early pancreatic cancer.
Proteomics is the study of the patterns of proteins made by an organism,
tissue, or cell and of the changes in these patterns that are associated
with various diseases.
What Did the Researchers Do and Find? The researchers started their
search for pancreatic cancer biomarkers by studying the plasma
proteome (the proteins in the fluid portion of blood) of mice genetically
engineered to develop cancers that closely resemble human pancreatic
tumors. Through the use of two techniques called high-resolution mass
spectrometry and acrylamide isotopic labeling, the researchers identified
165 proteins that were present in larger amounts in plasma collected
from mice with early and/or advanced pancreatic cancer than in plasma
from control mice. Then, to test whether any of these protein changes
were relevant to human pancreatic cancer, the researchers analyzed
blood samples collected from patients with pancreatic cancer. These
samples, they report, contained larger amounts of some of these
proteins than blood collected from patients with chronic pancreatitis, a
condition that has similar symptoms to pancreatic cancer. Finally, using
blood samples collected during a clinical trial, the Carotene and Retinol
Efficacy Trial (a cancer-prevention study), the researchers showed that
the measurement of five of the proteins present in increased amounts at
an early stage of tumor development in the mouse model discriminated
between people with pancreatic cancer and matched controls up to 13
months before cancer diagnosis.
What Do These Findings Mean? These findings suggest that in-depth
proteomic analysis of genetically engineered mouse models of human
cancer might be an effective way to identify biomarkers suitable for the
early detection of human cancers. Previous attempts to identify such
biomarkers using human samples have been hampered by the many
noncancer-related differences in plasma proteins that exist between
individuals and by problems in obtaining samples from patients with
early cancer. The use of a mouse model of human cancer, these findings
indicate, can circumvent both of these problems. More specifically, these
findings identify a panel of proteins that might allow earlier detection of
pancreatic cancer and that might, therefore, extend the life of some
patients who develop this cancer. However, before a routine screening
test becomes available, additional markers will need to be identified and
extensive validation studies in larger groups of patients will have to be
completed.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050123.
  The MedlinePlus Encyclopedia has a page on pancreatic cancer (in
English and Spanish). Links to further information are provided by
MedlinePlus
  The US National Cancer Institute has information about pancreatic
cancer for patients and health professionals (in English and Spanish)
  The UK charity Cancerbackup also provides information for patients
about pancreatic cancer
  The Clinical Proteomic Technologies for Cancer Initiative (a US National
Cancer Institute initiative) provides a tutorial about proteomics and
cancer and information on the Mouse Proteomic Technologies
Initiative
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